Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review

CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) is associated with poor survival compared with CD5-negative DLBCL. The clinical characteristics of CD5+ DLBCL are different from both CD5-negative DLBCL and other CD5+ B cell lymphomas. There is currently no promising chemotherapy for CD5+ DL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Zhang, Yaping, Wang, Xinfeng, Liu, Yifei, Sun, Chunfeng, Shi, Wenyu, Huang, Hongming
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Bedside to Bench Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5989800/
https://ncbi.nlm.nih.gov/pubmed/29611764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1449609
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados